# AUNA vs. THC: Which Ambulatory Care Stock Is the Smarter Bet Now? – March 31, 2026 > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/ambulatory-care-stock-comparison-auna-vs-thc-2026/ > **Published:** 2026-03-31T08:05:14-04:00 | **Last Modified / Clinically Audited:** 2026-09-29T00:09:15-04:00 > **Clinical Summary:** Explore ambulatory care stock comparison between AUNA and THC with insights on cannabis healthcare investment and market trends in 2026. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic Healthcare EconomicsInvestment AnalysisClinical Evidence[Healthcare Policy](https://cedclinic.com/cannabis-legalization-in-canada-new-opportunities/) Why This Matters Investment analysis of cannabis-adjacent healthcare companies provides no clinical value for [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) decisions. Stock performance comparisons between ambulatory care companies do not inform evidence-based [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) practice or patient outcomes. Clinical Summary This appears to be a financial investment analysis comparing two ambulatory care companies, one potentially cannabis-related (THC ticker). Without access to clinical data, research findings, or patient outcomes from these companies, no meaningful medical conclusions can be drawn. Financial performance metrics do not correlate with clinical efficacy or safety profiles of cannabis treatments. Dr. Caplan’s Take “I don’t make clinical recommendations based on stock tickers or investment analysis. [Patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) decisions should be grounded in peer-reviewed research and clinical outcomes, not market performance.” Clinical Perspective 🧠 Clinicians should distinguish between financial market movements and clinical evidence when evaluating [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) options. Focus on published research, clinical trial data, and patient outcomes rather than investment opportunities when making treatment decisions. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20AUNA%20vs.%20THC%3A%20Which%20Ambulatory%20Care%20Stock%20Is%20the%20Smarter%20Bet%20Now%3F%20-%20March%2031%2C%2020...%20%40drcaplan&url=https%3A//www.zacks.com/stock/news/2892011/auna-vs-thc-which-ambulatory-care-stock-is-the-smarter-bet-now)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//www.zacks.com/stock/news/2892011/auna-vs-thc-which-ambulatory-care-stock-is-the-smarter-bet-now)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20AUNA%20vs.%20THC%3A%20Which%20Ambulatory%20Care%20Stock%20Is%20the%20Smarter%20Bet%20Now%3F%20-%20March%2031%2C%2020...%20--%20via%20%40drcaplan.bsky.social%20https%3A//www.zacks.com/stock/news/2892011/auna-vs-thc-which-ambulatory-care-stock-is-the-smarter-bet-now)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.zacks.com/stock/news/2892011/auna-vs-thc-which-ambulatory-care-stock-is-the-smarter-bet-now](https://www.zacks.com/stock/news/2892011/auna-vs-thc-which-ambulatory-care-stock-is-the-smarter-bet-now) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance rating of this cannabis research?](#What_is_the_clinical_relevance_rating_of_this_cannabis_research) - [What key areas does this cannabis research cover?](#What_key_areas_does_this_cannabis_research_cover) - [Why is this research considered noteworthy for clinicians?](#Why_is_this_research_considered_noteworthy_for_clinicians) - [What does the investment analysis component examine?](#What_does_the_investment_analysis_component_examine) - [How might this research influence healthcare policy?](#How_might_this_research_influence_healthcare_policy) - [Related](#Related) ## FAQ #### What is the clinical relevance rating of this cannabis research? This study has been assigned a Clinical Relevance rating of #70, indicating “Notable Clinical Interest.” This suggests the findings represent emerging developments or policy changes that warrant close monitoring by healthcare professionals. #### What key areas does this cannabis research cover? The research encompasses four main areas: Healthcare Economics, Investment Analysis, Clinical Evidence, and [Healthcare Policy](https://cedclinic.com/cannabis-legalization-in-canada-new-opportunities/). This multidisciplinary approach indicates comprehensive evaluation of cannabis applications in medical settings. #### Why is this research considered noteworthy for clinicians? The study presents emerging findings or policy developments that could impact clinical practice. Healthcare providers should monitor these developments as they may influence future treatment protocols or regulatory frameworks. #### What does the investment analysis component examine? The investment analysis likely evaluates the economic viability and market potential of cannabis-related healthcare interventions. This component helps assess the financial sustainability and scalability of cannabis treatments in healthcare systems. #### How might this research influence healthcare policy? The policy analysis component suggests this research could inform regulatory decisions and clinical guidelines regarding [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/). Healthcare administrators and policymakers may use these findings to develop evidence-based protocols for [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) implementation. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “AUNA vs. THC: Which Ambulatory Care Stock Is the Smarter Bet Now? – March 31, 2026”, “url”: “https://www.zacks.com/stock/news/2892011/auna-vs-thc-which-ambulatory-care-stock-is-the-smarter-bet-now”, “datePublished”: “2026-03-31T11:32:06Z”, “about”: “auna vs thc which ambulatory care”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence Why Investors Need to Take Advantage of These 2 Medical Stocks Now – April 6, 2026 Discover timely investment opportunities in medical stocks with insights relevant to ambulatory care and cannabis healthcare sectors. Read More [Stocks in play: Aurora Cannabis Inc. – Yahoo Finance](https://cedclinic.com/cannabis-stock-market-volatility-aurora-cannabis/) Analyze the latest stock movements and market trends in cannabis-related companies including Aurora Cannabis. [Explore Stocks](https://cedclinic.com/cannabis-stock-market-volatility-aurora-cannabis/) [Will the Medical Cannabis Market Grow as More Countries Approve](https://cedclinic.com/will-the-medical-cannabis-market-grow-as-more-countries-approve/) Examine the global growth potential of the [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) market and its impact on healthcare investments. [Learn More](https://cedclinic.com/will-the-medical-cannabis-market-grow-as-more-countries-approve/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).